Announcements

Job offersmore »





Tweeting Growers

Top 5 - yesterday

  • No news has been published yesterday.

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




US: Broad files update to CRISPR-Cas9 portfolio

The Rockefeller University and the Broad Institute of MIT and Harvard have settled their disagreement regarding inventorship and ownership of certain Broad filings relating to the use of the CRISPR-Cas9 system in eukaryotic cells. Rockefeller believed that its faculty member Dr. Luciano Marraffini, co-author with Broad’s Dr. Feng Zhang, on a seminal paper published in Science in 2013, Multiplex Genome Engineering Using CRISPR/Cas Systems, should have been maintained in these Broad eukaryote filings.

The parties agreed to submit their dispute to binding arbitration, in which it was decided that inventorship on Broad’s eukaryote filings in US Patent 8,697,359, and Patent Cooperation Treaty (PCT) applications PCT/US2013/074667, PCT/US2013/074691, PCT/US2013/074736, PCT/US2013/074743, PCT/US2013/074812, PCT/US2013/074819, PCT/US2013/074825, PCT/US2013/074790 or PCT/US2013/074800; or US application 15/349,603 will remain unchanged. The Broad Institute manages a robust CRISPR-Cas9 patent portfolio including key CRISPR-Cas9 patents in the United States and Europe relating to use of CRISPR-Cas9 in eukaryotic cells.

In addition, the Broad Institute portfolio includes filings relating to the use of the CRISPR-Cas9 system in prokaryotic cells, on which Drs. Marraffini and Zhang are co-inventors and Rockefeller and Broad are joint owners.

The Broad Institute and Rockefeller make CRISPR tools freely available to the academic and nonprofit communities and issue non-exclusive licenses for most types of commercial research. In July, 2017, the institutions joined discussions to create a worldwide CRISPR-Cas9 licensing pool. For human therapeutics, the Broad Institute places limits on exclusivity through its Inclusive Innovation model, which offers one licensee exclusive use for a defined period (two years), followed by an open call for applications by other groups. In the case of CRISPR-Cas9, the two-year exclusive period has already ended. Parties interested in licensing the technology are invited to apply through the Broad website.

Publication date: 1/16/2018

 


 

Other news in this sector:

2/19/2018 "Innovation is not only genetics"
2/16/2018 US: More plantings of organic celery
2/16/2018 Documenting the value of genebanks
2/15/2018 Researchers find gene that may increase strawberry production
2/14/2018 Customising seeds for Thailand
2/14/2018 US (MI): Homespun seed catalog specializes in heirloom vegetables
2/8/2018 Genetic trigger adds branches to plants
2/8/2018 Bejo and Limagrain announce licensing deal on traits in vegetables
2/7/2018 New 'Tomato Expression Atlas' dives deep into the fruit's flesh
2/7/2018 "Sharing is multiplying, listening is appreciating"
2/7/2018 Blast from the past: 1929 tomato seeds
2/6/2018 Azerbaijan: New varieties of lemon & strawberry to be developed
2/2/2018 Planasa incorporates a new CEO for its subsidiary in Holland
2/2/2018 Research call on improving seed systems in Asia and Africa
2/1/2018 Rijk Zwaan strives to improve India’s food supply
1/31/2018 "High-tech genetics drives agriculture forward"
1/31/2018 Consequences of Brexit on Plant Variety Rights
1/29/2018 India: Growers told to go for dual purpose tomato breeds
1/29/2018 Aussies breed cukes and tomatoes for ingredients
1/29/2018 Tolima: new large tomato with a good taste